1 Podium Talk and 9 Posters Featuring Luminex Products for Infectious Disease Applications will be Presented
AUSTIN, Texas, April 7, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it will showcase its recently CE-IVD marked, sample to answer ARIES® molecular diagnostic system and related assays at the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Amsterdam April 9-12. The new ARIES® System headlines a growing list of featured products from the company for molecular diagnosis of infectious diseases that are designed to improve result accuracy outcomes while reducing overall costs.
Luminex offers a number of assay panels for use with the ARIES® System, including the CE-IVD marked ARIES® HSV 1&2 Assay, and GBS and Flu A/B & RSV Assays available for research use. The ARIES® System and ARIES® HSV 1&2 Assay received FDA clearance in October 2015 and were subsequently launched in the U.S. market. The company will also showcase its NxTAG® Respiratory Pathogen Panel (RPP), which detects 20 clinically relevant viral and bacterial respiratory pathogens and also recently received both CE-IVD marking and FDA clearance. Luminex employees will demonstrate new software called SYNCT™ and other tools in an "Experience Room" containing the ARIES® System, a MAGPIX® instrument, and NxTAG RPP plates within the Luminex booth space (#12) on the trade show floor. SYNCT software streamlines data analysis and reporting, and is specifically designed for the needs of molecular labs running ARIES® or NxTAG RPP assays to allow lab directors to manage their lab data from multiple workstations through a single interface.
"We are excited to formally introduce the ARIES® System to more than 10,000 virologists, medical microbiologists, laboratory directors, and consulting pathologists from Europe and around the world at this important conference, especially right on the heels of receiving a CE-IVD mark for the product," said Thomas Pracht, Managing Director, EMEIA, Luminex Corporation. "We worked closely with our customers on the design of both our ARIES® and NxTAG solutions, and initial response has been extremely favorable. Combined with our other products for molecular diagnosis of infectious diseases, we are proud to offer a robust selection of solutions that deliver cost-effective, rapid results to clinicians and researchers."
To learn more about Luminex technologies featured in the scientific program at ECCMID, download the full list of posters.
About the ARIES® System and HSV 1&2 Assay
The ARIES® System is a sample to answer molecular diagnostic system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. The ARIES® System uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and Batch testing of IVD and homebrew assays using MultiCode® Reagents when using a common Universal Assay Protocol. An integrated touchscreen PC eliminates the need for a separate computer, standalone keyboard, and mouse, maximizing valuable bench space.
The ARIES® HSV 1&2 Assay is a real-time PCR-based qualitative in vitro diagnostic test for the direct detection and typing of herpes simplex virus (HSV 1&2) DNA in cutaneous or mucocutaneous lesion specimens from symptomatic patients, or in cerebrospinal fluid (CSF) from patients suspected of HSV infections of the central nervous system. The test is indicated for use with symptomatic individuals to aid in the diagnosis of HSV infections. The assay is not intended to be used for prenatal screening. The ARIES® HSV 1&2 Assay is indicated for use on the ARIES® System.
The NxTAG Respiratory Pathogen Panel is CE-marked in Europe, and FDA-cleared in the U.S. The NxTAG Respiratory Pathogen Panel is an assay that detects relevant viral and bacterial respiratory pathogens, including the atypical bacteria Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila. The panel is the only respiratory assay that enables laboratories to easily and simultaneously detect these respiratory pathogens in a single, closed tube system and in a format that scales to accommodate changes in throughput needed to respond to seasonal changes in demand, especially during flu season. The NxTAG Respiratory Pathogen Panel requires only minutes of hands-on time with no upstream reagent preparation. The innovative tube strip design offers laboratories the flexibility to process a single sample or up to 96 samples per run, without wasting consumables or reagents. Total turnaround time is only about three hours for 96 samples (excluding extraction).
About Luminex Corporation
Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology, and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research, and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward- looking statements in this release include statements regarding the development and testing progress of our pipeline products, and the regulatory approvals thereof. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should", and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
SOURCE Luminex Corporation